Andrew R Clamp Selected Research

Ovarian Epithelial Carcinoma

10/2023	Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.
11/2022	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
1/2022	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
1/2022	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
1/2021	Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
1/2020	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
1/2020	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
12/2019	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
1/2019	Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew R Clamp Research Topics

Disease

18	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 06/2005
15	Carcinoma (Carcinomatosis) 01/2023 - 03/2005
12	Neoplasms (Cancer) 01/2023 - 06/2005
9	Ovarian Epithelial Carcinoma 10/2023 - 01/2019
2	Fatigue 05/2024 - 01/2023
2	Disease Progression 01/2020 - 01/2011
2	Colorectal Neoplasms (Colorectal Cancer) 05/2014 - 11/2009
1	Fistula 05/2024
1	Anemia 01/2023
1	Nausea 01/2023
1	Fallopian Tube Neoplasms 02/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Proteinuria 05/2014
1	Hypertension (High Blood Pressure) 05/2014
1	Prostatic Neoplasms (Prostate Cancer) 02/2010
1	Neoplasm Metastasis (Metastasis) 11/2009
1	Pathologic Neovascularization 12/2006
1	Endometrial Neoplasms (Endometrial Cancer) 11/2005
1	Adenocarcinoma 06/2005

Drug/Important Bio-Agent (IBA)

16	PlatinumIBA 05/2024 - 01/2011
8	Paclitaxel (Taxol)FDA LinkGeneric 05/2024 - 02/2019
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2024 - 11/2005
7	Biomarkers (Surrogate Marker)IBA 11/2022 - 06/2005
6	Bevacizumab (Avastin)FDA Link 01/2023 - 09/2007
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 01/2018
6	rucaparibIBA 12/2022 - 01/2020
4	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 12/2019
3	AntigensIBA 01/2023 - 01/2011
2	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 01/2023
2	olaparibIBA 01/2023 - 01/2023
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2020 - 10/2020
2	Cisplatin (Platino)FDA LinkGeneric 02/2019 - 01/2018
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 11/2005 - 06/2005
1	cediranib (AZD2171)IBA 05/2024
1	vistusertibIBA 01/2023
1	Formaldehyde (Formol)FDA Link 01/2023
1	ParaffinIBA 01/2023
1	Peptides (Polypeptides)IBA 01/2022
1	paragonIBA 10/2021
1	Poly Adenosine Diphosphate RiboseIBA 01/2021
1	pazopanib FDA Link 01/2020
1	fosbretabulin (combretastatin A4)IBA 01/2020
1	chemotactic factor inactivatorIBA 01/2020
1	Gemcitabine FDA Link 02/2019
1	antineoplaston A10 (A 10)IBA 01/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2018
1	Tyrosine Kinase InhibitorsIBA 05/2014
1	Angiogenesis InhibitorsIBA 05/2014
1	Hormones (Hormone)IBA 02/2010
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2007
1	Sorafenib (BAY 43-9006)FDA Link 09/2007
1	Sunitinib (Sutent)FDA Link 09/2007
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2005
1	OligosaccharidesIBA 11/2005
1	CytokinesIBA 06/2005
1	Heparitin Sulfate (Heparan Sulfate)IBA 06/2005
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 03/2005

Therapy/Procedure

17	Therapeutics 01/2023 - 09/2007
12	Drug Therapy (Chemotherapy) 05/2024 - 09/2007
2	Intravenous Infusions 01/2022 - 02/2019
2	Cytoreduction Surgical Procedures 01/2021 - 01/2020
2	Home Parenteral Nutrition 01/2020 - 12/2019
1	Retreatment 01/2023
1	Neoadjuvant Therapy 01/2021
1	Ligation 01/2019